Eli Lilly and Company and Incyte Corporation announced that the FDA has approved the 2-mg dose of Olumiant (baricitinib), a...
Eli Lilly and Company and Incyte announced that the FDA has approved Olumiant (baricitinib), a once-daily pill, as a first-in-disease systemic treatment for adults with severe alopecia areata (AA), available as 4-mg, 2-mg and 1-mg tablets.
The National Institute for Health and Care Excellence (NICE) in draft guidelines has recommended, JAK inhibitor, Olumiant (baricitinib) from Eli...
Eli Lilly and Company will present new data for Olumiant (baricitinib) at the virtual European Congress of Rheumatology (EULAR 2020) taking place June 3-6, 2020.
Through new analyses of BREEZE-AD5 Phase III clinical trial data and an extended safety analysis across multiple trials , Eli Lilly and Company and Incyte's Olumiant (baricitinib) 2-mg tablet taken once daily showed improvement in key measured treatment outcomes compared to placebo, and helped further characterize the long-term safety profile in adults with moderate to severe atopic dermatitis (AD).
Eli Lilly and Company and Incyte Corporation announced that the European Commission has granted marketing authorisation for Olumiant (baricitinib) 4...
Eli Lilly and Incyte announced that The New England Journal of Medicine has published peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2) of patients treated with Olumiant (baricitinib) in combination with Veklury (remdesivir) for treating COVID-19.
Eli Lilly and Incyte announced detailed results from two pivotal Phase III trials (BRAVE-AA1 and BRAVE-AA2), which found once-daily Olumiant (baricitinib) 4-mg was superior to placebo in achieving significant scalp hair regrowth as early as 24 weeks in adults with severe alopecia areata (AA) as defined by at least 50% scalp hair loss at baseline.
Olumiant (baricitinib) from Eli Lilly and Incyte, maintained a consistent safety profile in a long-term, integrated safety analysis of patients with rheumatoid arthritis (RA) who received Olumiant for 14,744 patient years of exposure, in line with previously published findings.
Lilly and Company and Incyte will present data from post-hoc analyses that suggested Olumiant(baricitinib) 4 mg tablet reduced pain and duration of morning joint stiffness, and improved overall physical function at 12 weeks, among patients with moderate to severe rheumatoid arthritis (RA), compared to Humira (adalimumab) and placebo.